Allovir, Inc.

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

NEW YORK , March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc.. Shareholders who purchased shares of ALVR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70989&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline 0 ALVR

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71009&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against AlloVir, Inc.(ALVR)

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70875&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AlloVir, Inc. (ALVR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70837&wire=1 or contact Joseph E. Levi, Esq.

AlloVir, Inc. Class Action: Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70808&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AlloVir, Inc. (ALVR) should contact Levi & Korsinsky about pending Class Action - ALVR

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70812&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALVR

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70749&wire=1 or contact Joseph E. Levi, Esq.

March 19, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALVR

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70684&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc. (ALVR) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK , March 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the "Class Period"), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased AlloVir securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR

NEW YORK , March 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AlloVir investors who were adversely affected by alleged securities fraud between March 22, 2022 and December 21, 2023.

AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=70358&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / March 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=69824&wire=1 or contact Joseph E. Levi, Esq.

Investors in AlloVir, Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

NEW YORK , March 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc.. Shareholders who purchased shares of ALVR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

LOS ANGELES, CA / ACCESSWIRE / March 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AlloVir investors who were adversely affected by alleged securities fraud between March 22, 2022 and December 21, 2023.

Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK , March 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the "Class Period"), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased AlloVir securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=69361&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir Lawsuit - ALVR

LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=69034&wire=1 or contact Joseph E. Levi, Esq.

News for Allovir, Inc. Stock (ALVR)